GlycoMimetics, Inc. (NASDAQ: GLYC) Starts Presentation at 30th Annual ROTH Conference
GlycoMimetics (NASDAQ: GLYC) is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a phase 3 clinical trial being conducted by the company’s strategic collaborator, Pfizer. The company's wholly-owned drug candidate, GMI-1271, was evaluated in a phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a phase 1…







